论文部分内容阅读
目的:评价垂体后叶素治疗肺结核咯血患者的临床疗效。方法:将我院收治的88例肺结核咯血患者平均分成试验组和对照组,给予对照组患者酚妥拉明治疗,给予试验组患者垂体后叶素治疗。结果:试验组患者的临床治疗总有效率明显高于对照组(P<0.05),咯血止血时间为(2.9±0.5)d,明显早于对照组患者的(4.5±0.9)d(P<0.05),出血量为(275.3±56.2)ml,明显少于对照组患者的(451.9±73.8)ml(P<0.05),药物不良反应发生率为22.7%,明显高于对照组患者的9.1%(P<0.05)。结论:垂体后叶素治疗肺结核咯血临床效果显著,但药物不良反应发生率较高,临床应根据患者机体状况慎重选择治疗药物。
Objective: To evaluate the clinical efficacy of pituitrin in the treatment of patients with pulmonary tuberculosis and hemoptysis. Methods: 88 cases of pulmonary tuberculosis patients with hemoptysis admitted to our hospital were divided equally into experimental group and control group. Patients in control group were treated with phentolamine, and patients in experimental group were given pituitrin treatment. Results: The total effective rate of clinical trial in trial group was significantly higher than that in control group (P <0.05). The duration of hemoptysis was (2.9 ± 0.5) d, significantly earlier than that in control group (4.5 ± 0.9) d (P <0.05) ), The amount of bleeding was (275.3 ± 56.2) ml, significantly lower than that of the control group (451.9 ± 73.8) ml (P <0.05). The incidence of adverse drug reactions was 22.7%, which was significantly higher than that of the control group (9.1% P <0.05). Conclusion: Pituitrin treatment of tuberculosis hemoptysis clinical effect is significant, but the incidence of adverse drug reactions higher clinical selection of drugs should be based on the patient’s condition carefully.